Combination chemotherapy and hormone therapy in patients with hormone receptor positive and HER2 negative metastatic breast cancer.

ABSTRACT: There is sparse data on the outcomes of combined chemotherapy and hormonal therapy (CHT) in patients with metastatic breast cancer (MBC). This retrospective analysis of HR-positive, HER2-negative MBC patients treated between January 2015 and December 2020 with a combination of chemotherapy (capecitabine or oral cyclophosphamide) and hormonal therapy evaluated their progression-free survival (PFS) and overall survival (OS).The study included 224 patients with a median age of 53 (26-91) years, a median of 3 (0-12) prior treatment lines and a median follow-up of 21.2 (1.7-87.0) months. There were 195 (87.1%) PFS events and 154 (68.8%) deaths, with a median PFS of 8.8 (95% CI 7.0-10.6) months and a median OS of 16.7 (95% CI 13.5-19.9) months. In univariable analyses, ECOG PS (≤ 1 vs. ≥ 2, PFS

SUBMITTER: Bajaj K 

PROVIDER: S-EPMC12316914 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature